FundraiseSep 10, 2026, 08:45 UTC

Connecta raises €3.1M to fund Fragile X trial through 2027 data readout

What's the deal? Barcelona-based Connecta Therapeutics has closed a €3.1 million ($3.6 million) early-stage financing led by new investor Clave Capital. Existing backers Inveready, CDTI Innvierte, and Prous Institute for Biomedical Research also took part.

What's the endgame? Connecta is a clinical-stage biotech developing neuroplasticity modulators for central nervous system disorders. Its lead drug, CTH120, is a potential first-in-class treatment for Fragile X syndrome (FXS), a rare, currently untreatable neurodevelopmental disorder that impairs cognition and behaviour.

Why now? The proceeds will fund completion of an ongoing Phase IIa trial of CTH120 in 30 adult males with FXS, initiated in June 2026. Topline data is expected in mid-2027.

The trial runs at the Hospital del Mar Research Institute and the Parc Taulí Research and Innovation Institute Foundation, with biomarker work at the Centre for Genomic Regulation. It is separately funded by the Spanish Ministry of Science, Innovation and Universities and the EU's NextGeneration EU program.

What they said: "This represents a significant milestone for CONNECTA and supports our efforts to advance CTH120 for FXS," said co-founder and chief executive officer Jordi Fàbrega. Ignacio Prieto Fernández of Clave Capital, who joins Connecta's board, cited the company's "differentiated approach to targeting neuroplasticity in FXS."

The signal: The round is modest by biotech standards, sitting near the middle of comparable deals. But it targets a defined near-term catalyst — a 2027 readout — that could validate CTH120's approach in a disease with no approved treatment.